Related Experiment Video
Updated: Feb 8, 2026

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
Pharmacological Interventions for Vascular Targeting in Retinopathy of Prematurity: An Experimental Study
Purpose:
This study was conducted to evaluate the pharmacological interventions to target vascular proliferation in the Retinopathy of Prematurity (ROP).
Methods:
Protein Kinase C modulator (Bryostatin), tubulin polymerization inhibitor (Dolastatin 10), antiVEGF (Bevacizumab) and a non-specific VEGF inhibitor (Thalidomide) were screened in Retinopathy of Prematurity (ROP) model. The retinal vasculature was evaluated by calculating the tortuosity indices of vessels and electroretinography responses in terms of ‘b’ wave amplitude and was recorded from ROP rats on postnatal Day 17 and Day 25.
Results:
Retinopathy was seen in the form of tortousity of vessels at the posterior pole with arteries being affected more than veins. Maximum reduction in tortousity of vessels and the highest ‘b’ wave amplitude noted in bryostatin with a significant correlation between the two.
Conclusion:
Bryostatin showed a potential anti-angiogenic effect on the progression of ROP and may hold a promising future in the treatment of ROP.
Insights
Bryostatin effectively reduced abnormal blood vessel growth in a Retinopathy of Prematurity (ROP) model, showing promise for treating this eye condition in premature infants.
Area of Science:
- Ophthalmology
- Pharmacology
- Developmental Biology
Background:
- Retinopathy of Prematurity (ROP) is a leading cause of blindness in premature infants.
- Vascular proliferation in the retina is a hallmark of ROP, leading to vision impairment.
Purpose of the Study:
- To evaluate pharmacological interventions for targeting vascular proliferation in Retinopathy of Prematurity (ROP).
- To assess the efficacy of Bryostatin, Dolastatin 10, Bevacizumab, and Thalidomide in an ROP model.
Main Methods:
- Screening of Bryostatin, Dolastatin 10, Bevacizumab, and Thalidomide in a rat model of ROP.
- Evaluation of retinal vasculature using tortuosity indices.
- Assessment of electroretinography responses (b wave amplitude) on postnatal days 17 and 25.
Main Results:
- ROP presented as vessel tortuosity, primarily affecting arteries.
- Bryostatin demonstrated the maximum reduction in vessel tortuosity.
- Bryostatin treatment correlated with the highest 'b' wave amplitude in electroretinography.
Conclusions:
- Bryostatin exhibits a potential anti-angiogenic effect in the progression of ROP.
- Bryostatin may offer a promising therapeutic strategy for treating Retinopathy of Prematurity.
More Related Videos
08:49Assessing Changes in Volatile General Anesthetic Sensitivity of Mice after Local or Systemic Pharmacological Intervention
Published on: October 16, 2013
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
Nursing Interventions II: Selecting and Classifying the Nursing Interventions
Imaging Studies VII: Vascular Imaging
Seedless Vascular Plants
Community Based Intervention
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Operant Conditioning Intervention
In operant conditioning, behaviors that are...